ARTICLE | Clinical News
AZD8931: Phase Ib/IIa started
August 27, 2012 7:00 AM UTC
Cancer Research UK (London, U.K) said Oxford University began a dose-escalation, open-label, U.K. Phase Ib/IIa trial to compare AZD8931 plus Xelox chemotherapy (a combination of oral Xeloda capecitabine and IV oxaliplatin) vs. Xelox alone in up to 48 patients. AstraZeneca is supplying AZD8931 and will provide additional funding. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xelox and Xeloda. ...